Prothena Corporation plc (PRTA) just the other week announced data from its phase 3 AFFIRM-AL clinical trial using birtamimab for the treatment of patients with AL amyloidosis. The really bad news ...
Tenax Therapeutics (TENX) is in a very good position as far as its drug development plan goes for its drug levosimendan. That's because it is already in the process of running the ongoing phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback